Geron

Geron

Yahoo Finance • 30 days ago

Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands

Key Points Interested in Geron Corporation? Here are five stocks we like better. Geron expects 2026 RYTELO revenue of approximately $230 million to $240 million, toward the midpoint to high end of its previously issued $220 million-$240 m... Full story

Yahoo Finance • last month

Geron to Present at Upcoming Investor Conferences

Geron Corporation FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announc... Full story

Yahoo Finance • 2 months ago

Geron (GERN) Is Up 14.7% After Issuing First RYTELO Revenue Guide And Narrowing Losses - Has The Bull Case Changed?

In the second quarter of 2026, Geron Corporation reported revenue of US$57.48 million versus US$49.04 million a year earlier, a net loss of US$16.68 million, first-half revenue of US$109.32 million, and a reduced first-half net loss of US$... Full story

Yahoo Finance • 2 months ago

Top Biotech Gainers: ATTO Debuts, AMWL Cuts Loss, PRGO Returns To The Black, URGN Hits New High

(RTTNews) - Today's top biotech gainers include Attovia Therapeutics, which surged following its Nasdaq debut; American Well, after reporting a narrower loss; Perrigo, which swung back to profit; and UroGen Pharma, following strong second-... Full story

Yahoo Finance • 2 months ago

Geron Corporation Q2 2026 Earnings Call Summary

Geron Corporation Q2 2026 Earnings Call Summary - Moby Strategic Execution and Commercial Momentum Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 p... Full story

Yahoo Finance • 2 months ago

Geron Q2 Earnings Call Highlights

Key Points Interested in Geron Corporation? Here are five stocks we like better. Geron reported strong second-quarter performance, with revenue rising 17% year over year to $57.5 million and first-half revenue up approximately 24%. The co... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * The Walt Disney Company (DIS [https://seekingalpha.com/symbol/DIS]) * Eli Lilly and Company (LLY [https://seekingalpha.com/symbol/LLY]) * Shopify (SHOP [https://seeking... Full story

Yahoo Finance • 3 months ago

Geron (GERN) Grants Inducement Stock Options to New Employees

Geron Corporation (NASDAQ:GERN) is one of the 10 Fastest Growing Tech Penny Stocks to Buy. On June 18, 2026, Geron Corporation (NASDAQ:GERN) reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,... Full story

Yahoo Finance • 3 months ago

Geron Announces Appointment of Chinmaya Rath as Chief Business Officer

FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Chinm... Full story

Yahoo Finance • 4 months ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690... Full story

Yahoo Finance • 5 months ago

Geron Q1 Earnings Call Highlights

Geron logo Key Points Q1 net revenue of $61.8 million (up 31% YoY) and Geron reiterated full‑year Rytelo guidance of $220–240 million, noting growth is weighted to H2 2026 while gross‑to‑net rose to 21% (expected low‑mid 20s for the year... Full story

Yahoo Finance • 6 months ago

Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal Officer

Geron Corporation (NASDAQ:GERN) is one of the best growth stocks under $10 to invest in. On April 13, Geron Corporation appointed Timothy Williams as Executive Vice President, Chief Legal Officer, and Corporate Secretary. A seasoned legal... Full story

Yahoo Finance • 6 months ago

Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026

FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release it... Full story

Yahoo Finance • 8 months ago

Geron Corporation Q4 2025 Earnings Call Summary

Geron Corporation Q4 2025 Earnings Call Summary - Moby Strategic Alignment and Commercial Evolution Transitioned from a clinical-stage entity to a commercially minded organization through a strategic restructuring and leadership strength... Full story

Yahoo Finance • 8 months ago

Geron Q4 Earnings Call Highlights

Geron logo Key Points Geron reported strong commercial traction for RYTELO with Q4 net revenue of $48 million, full-year 2025 sales of $184 million, and 2026 guidance of $220–$240 million, driven by 9% quarter-over-quarter demand growth,... Full story

Yahoo Finance • 8 months ago

Geron falls as Q4 results miss expectations

[Close up image of wooden cubes with alphabet Q4 on office desk.] mohd izzuan Shares of Geron Corporation (GERN [https://seekingalpha.com/symbol/GERN]) lost ~15% in the premarket on Wednesday after the cancer drug developer missed Street... Full story

Yahoo Finance • 10 months ago

Geron strategic restructuring plan focuses on Rytelo growth

[Scissors separating employees on colorful blocks representing staff reduction] * Geron said that as part of its strategic restructuring plan, it will focus [https://seekingalpha.com/pr/20336521-geron-corporation-announces-strategic-res... Full story

Yahoo Finance • 10 months ago

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independ... Full story

Yahoo Finance • 12 months ago

GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Geron (GERN) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder of Geron securities between Februar... Full story

Yahoo Finance • 12 months ago

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders... Full story